magicmine/iStock via Getty Images
Biotech is hard. Most biotechs never manage to develop one drug that can get through the FDA approval process, let alone two. With Lexicon Pharmaceuticals (LXRX), though, investors are getting a difficult lesson that while…

Click here to view the original article.